{"entity":{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","aka":[],"tldr":"Where chemotherapy began (Farber, 1948) and where much of modern breast, lung, and myeloma oncology was defined.","summary":"Dana-Farber Brigham Cancer Center in Boston is where chemotherapy began, with Farber's aminopterin remissions in 1948, and through Dana-Farber/Harvard Cancer Center it is the largest NCI-designated centre by grant funding and fifteenth in the Newsweek/Statista oncology list. Its firsts include the discovery of EGFR mutations in lung cancer by Jänne and Johnson, KEYNOTE-522 leadership by Tolaney with Schmid in triple-negative breast cancer, Anderson's myeloma drug development and the Profile genomic testing programme. Nuclide links it to BWEL and RASolute 302, to pathology foundation models from the Mahmood and Yu labs, to the Cancer Dependency Map and clonal haematopoiesis papers, and to people including Paul G. Richardson, Benjamin L. Ebert and Ann H. Partridge. Data silos are the bottleneck Nuclide records against it. Its breast, lung, myeloma and paediatric programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.dana-farber.org"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Boston","country":"US","lat":42.338,"lng":-71.108,"institutionType":"cancer-center","website":"https://www.dana-farber.org","nci":"comprehensive","newsweekOncology2026":15,"university":"Harvard University","programs":["Breast oncology (KEYNOTE-522, ADCs)","Lung cancer genomics","Myeloma","Paediatric oncology"]},"route":"/institutions/dana-farber/","neighbours":{"indication":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/"},{"id":"neuroblastoma","kind":"indication","name":"Neuroblastoma (paediatric)","route":"/indications/neuroblastoma/"},{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/"},{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"bottleneck":[{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/"}]}}